Nanobiotix Shares Decline Despite +844% Yearly Increase and Raised Target
On Thursday midday, Nanobiotix fell by 2.76% to €28.20 in a downward trending Parisian market, with the CAC 40 losing 0.39% during the session. This temporary decline occurs even as the French medtech company's stock has shown a spectacular trajectory over the year, with a gain of more than 844%. On the same day, analyst firm Kempen raised its price target for the stock.
Kempen's Updated Recommendation
On March 12, the research firm Kempen released an update on its recommendation for Nanobiotix, raising its price target from €22 to €27, while maintaining a buy rating. However, with the current stock price at €28.20, it trades slightly above this new target, implying a potential downside of about 4.3% from the last quoted price. This gap between the market price and the revised target may help explain the selling pressure observed during the session. Over the last three months, Nanobiotix has risen nearly 42%, driven by growing interest in its enhanced radiotherapy technologies. The annual performance, over 840%, reflects a significant rerating of the case over the past twelve months, although the weekly decline of 2.42% indicates a cooling-off period after a pronounced upward movement.
Technical Perspective
Technically, the stock is significantly above its 50-day moving average, located at €21, representing a gap of more than 34%. This setup reflects the strength of the bullish trend that has been underway for several weeks but also indicates a significant distance from intermediate support levels. The nearest resistance is at €33.50, a threshold the stock has not yet tested. The RSI, an indicator measuring the speed and magnitude of price movements, stands at 67: a high level but not crossing into the conventionally set overbought zone of 70. This suggests that buying pressure remains but is approaching a potential saturation point. The monthly volatility, calculated at 26.52%, confirms the extent of recent fluctuations and calls for cautious interpretation of daily variations in this Parisian market-listed case.
